Nippon Soda Co., Ltd. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nippon Soda Co., Ltd.


High viscosity grade Nisso HPC-H (hydroxypropyl cellulose) offers advantages as a controlled release polymer when compared to HPMC in a sustained release matrix tablet application. In a direct compression application, HPC-H (fine powder type) sustains drug release more effectively than HPMC in the case of equivalent viscosity of the two polymers. Further, HPC-H has equivalent control release performance to HPMC 100000 while HPC-H has much lower viscosity, and this result is found when the tablet is prepared using either direct compression or wet granulation method.

Fig. 1: Effect of CR material (HPC vs HPMC, direct compression method)

Effect of CR Material (DC Method) is as shown in Fig 1. In the case of DC method, HPC-H-FP sustained drug release more than HPMC 4000, and showed equivalent release control performance to HPMC 100000 while its viscosity was much lower.

Fig 2: Effect of CR Material (HPC vs. HPMC, wet granulation method)

Effect of CR Polymer (WG Method) is as shown in Fig. 2. In the case of WG method, much difference was not seen in comparison of drug release from tablet prepared by HPC-H and HPC-H-FP. Also, Both HPC-H and HPC-H-FP showed equivalent release control performance to HPMC 100000. Drug release from tablet prepared by HPMC 4000 was much faster than the others.

Click here to download a white paper with complete data.

Contact info:
Catherine Cote
c.cote@nissoamerica.com
Nisso America Inc.
88 Pine Street, 14th Fl
New York, NY 10005
+1-212-490-0350
www.nissoexcipients.com

Nisso Chemical Europe GmbH
Naoki Kuwada
kuwada@nisso-chem.de
+49-(0)-211-1306686-0

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search

Click here